2,938 changes Notice, last 7 days
Professional Recovery Network, Fees and CE Updates
Professional Recovery Network, Fees and CE Updates
Rule, Disciplinary Action, & Remedial Plan Summaries
Rule, Disciplinary Action, & Remedial Plan Summaries
Health Canada Health Product Safety Recap
Health Canada has issued its February 2026 Health Product InfoWatch, detailing recalls for Teva Octreotide due to GMP deficiencies and unauthorized health products. It also announces a consultation on controlling zuranolone under the Controlled Drugs and Substances Act.
Health Canada Health Product InfoWatch - February 2026
Health Canada's February 2026 Health Product InfoWatch includes a monthly recap of safety information, including a recall of Teva Octreotide and advisories on unauthorized products. It also announces a consultation on controlling zuranolone and new market authorizations with conditions.
Therapeutic Product Approvals and Indications List Update
The Health Sciences Authority (HSA) of Singapore has published updated lists of new therapeutic product approvals and new indications for registered therapeutic products, effective March 2026. These lists are intended for healthcare professionals and industry members.
HSA Achieves WHO ML4 Recognition for Medical Devices, Expands Biomedical Role
The Health Sciences Authority (HSA) in Singapore has achieved the highest World Health Organization (WHO) Maturity Level (ML4) for medical devices regulatory systems, becoming the first national authority globally to do so. HSA is also expanding its economic role to support the biomedical sector's growth.
Raymond Chua's address at 29th Medical Device Regulators Forum
Raymond Chua's address at 29th Medical Device Regulators Forum
HSA Deepens International Partnerships for Biomedical Sector Growth
The Health Sciences Authority (HSA) of Singapore has announced deepened collaborations with Malaysia and Uzbekistan to facilitate access to medicines and medical devices. These partnerships include a formalised Medical Device Regulatory Reliance Programme with Malaysia and a Memorandum of Understanding with Uzbekistan for broader regulatory cooperation.
TGA Safety Advisory: Counterfeit GLP-1 Weight Loss Products
The Therapeutic Goods Administration (TGA) has issued an updated safety advisory regarding counterfeit weight loss products falsely claiming to contain GLP-1 receptor agonists. Laboratory testing confirmed these products contain no active GLP-1 ingredients and are not included in the Australian Register of Therapeutic Goods.
TGA Safety Alert: Natures Valley Collagen Builder contains undeclared sildenafil
The Therapeutic Goods Administration (TGA) has issued a safety alert regarding Natures Valley Collagen Builder tablets, which were found to contain undeclared sildenafil. Consumers are warned that the product poses a serious health risk and should not be taken.
Get alerts for ""
We'll email you when new changes match this search.
Free. Unsubscribe anytime.